Barclays raises Globus Medical stock price target to $106 on margin strength

Published 08/08/2025, 18:12
Barclays raises Globus Medical stock price target to $106 on margin strength

Investing.com - Barclays (LON:BARC) raised its price target on Globus Medical (NYSE:GMED) to $106.00 from $103.00 on Friday, while maintaining an Overweight rating on the medical device company’s stock. According to InvestingPro data, the stock currently trades at $57.78, significantly below its Fair Value, with analysts’ targets ranging from $65 to $105.

The price target increase follows Globus Medical’s earnings beat, which was driven by 7.4% underlying U.S. spine growth, sales and margin upside from NVRO, and improving robot trends. The company maintains strong fundamentals with a healthy gross profit margin of 67% and revenue growth of 17.4% over the last twelve months.

Barclays noted that Globus Medical is on track to exit the year with over 30% EBITDA margins and improving organic growth, supporting the firm’s positive outlook on the stock.

The new $106 price target is based on a 13.5x EV/EBITDA multiple on Barclays’ projected next-twelve-months EBITDA of $1.03 billion, looking one year forward.

The increase in the price target primarily reflects declines in projected net debt and the rolling forward of the EBITDA basis by one quarter, now comprising the second half of 2026 and first half of 2027.

In other recent news, Globus Medical reported preliminary second-quarter 2025 revenue of $745 million, surpassing the consensus estimate of $740 million. However, the company’s base business results of $651 million fell short of the $664 million consensus expectation. The company also announced the appointment of Keith Pfeil as the new President and CEO, effective July 18, 2025, following Daniel Scavilla’s resignation. In addition, Globus Medical has expanded its Excelsius navigation capabilities with the introduction of the DuraPro oscillating system, aimed at enhancing spine surgery workflows. Meanwhile, Needham maintained its Hold rating on Globus Medical amid the CEO transition and revenue announcements. Piper Sandler reiterated its Overweight rating on the company, despite challenges following disappointing first-quarter results and reactions to the Nevro acquisition. Separately, Dentsply Sirona named Daniel Scavilla as its new CEO, effective August 1, 2025, following his departure from Globus Medical. Scavilla’s leadership at Globus included a significant $3 billion acquisition, highlighting his extensive experience in the medical technology industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.